Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CGON |
---|---|---|
09:32 ET | 10679 | 31.16 |
09:36 ET | 1904 | 31.37 |
09:38 ET | 1250 | 31.195 |
09:39 ET | 218 | 31.42 |
09:41 ET | 2786 | 31.13 |
09:43 ET | 300 | 31.235 |
09:45 ET | 3982 | 31.19 |
09:48 ET | 1295 | 31.155 |
09:50 ET | 1667 | 31.64 |
09:52 ET | 116 | 31.67 |
09:54 ET | 1398 | 31.58 |
09:56 ET | 516 | 31.48 |
09:57 ET | 214 | 31.55 |
09:59 ET | 991 | 31.35 |
10:01 ET | 700 | 31.415 |
10:03 ET | 1106 | 31.34 |
10:06 ET | 2752 | 31.01 |
10:08 ET | 1108 | 31.13 |
10:10 ET | 1504 | 31.25 |
10:12 ET | 607 | 31.265 |
10:14 ET | 6063 | 31.4 |
10:15 ET | 2231 | 31.265 |
10:17 ET | 623 | 31.29 |
10:19 ET | 1007 | 31.28 |
10:21 ET | 2219 | 31.07 |
10:24 ET | 1067 | 31.215 |
10:26 ET | 4184 | 31.35 |
10:28 ET | 514 | 31.36 |
10:30 ET | 1581 | 31.22 |
10:32 ET | 700 | 31.21 |
10:33 ET | 600 | 31.28 |
10:35 ET | 2245 | 31.29 |
10:37 ET | 500 | 31.19 |
10:39 ET | 1171 | 31.09 |
10:42 ET | 267 | 31.145 |
10:44 ET | 410 | 31.125 |
10:46 ET | 400 | 31.135 |
10:48 ET | 300 | 31.135 |
10:50 ET | 300 | 31.14 |
10:51 ET | 422 | 31.135 |
10:55 ET | 400 | 31.12 |
10:57 ET | 519 | 31.12 |
11:00 ET | 215 | 31.125 |
11:02 ET | 1340 | 31.12 |
11:04 ET | 167 | 31.12 |
11:06 ET | 5148 | 31.31 |
11:08 ET | 321 | 31.31 |
11:11 ET | 1487 | 31.17 |
11:13 ET | 1100 | 31.185 |
11:15 ET | 367 | 31.09 |
11:18 ET | 917 | 31.075 |
11:20 ET | 467 | 31.05 |
11:22 ET | 400 | 31.11 |
11:24 ET | 300 | 31.05 |
11:26 ET | 2874 | 30.965 |
11:27 ET | 514 | 30.945 |
11:29 ET | 1400 | 30.9 |
11:31 ET | 1300 | 31.005 |
11:33 ET | 500 | 30.91 |
11:36 ET | 400 | 30.89 |
11:38 ET | 467 | 30.95 |
11:40 ET | 1971 | 30.975 |
11:42 ET | 819 | 30.98 |
11:44 ET | 1007 | 30.91 |
11:45 ET | 644 | 30.92 |
11:47 ET | 210 | 30.95 |
11:49 ET | 1122 | 30.99 |
11:51 ET | 4933 | 31.38 |
11:56 ET | 1538 | 31.395 |
11:58 ET | 1492 | 31.47 |
12:00 ET | 500 | 31.57 |
12:02 ET | 707 | 31.57 |
12:03 ET | 1117 | 31.575 |
12:05 ET | 36305 | 31.58 |
12:07 ET | 1400 | 31.59 |
12:09 ET | 900 | 31.595 |
12:12 ET | 1300 | 31.42 |
12:14 ET | 267 | 31.36 |
12:16 ET | 1204 | 31.32 |
12:20 ET | 1011 | 31.26 |
12:21 ET | 9566 | 31.425 |
12:23 ET | 200 | 31.425 |
12:27 ET | 308 | 31.4 |
12:30 ET | 1862 | 31.635 |
12:32 ET | 636 | 31.67 |
12:34 ET | 500 | 31.7 |
12:36 ET | 300 | 31.675 |
12:38 ET | 100 | 31.7225 |
12:39 ET | 800 | 31.68 |
12:41 ET | 1572 | 31.51 |
12:43 ET | 100 | 31.59 |
12:45 ET | 100 | 31.56 |
12:48 ET | 604 | 31.56 |
12:50 ET | 400 | 31.53 |
12:52 ET | 3565 | 31.475 |
12:54 ET | 1441 | 31.445 |
12:56 ET | 300 | 31.37 |
12:57 ET | 629 | 31.41 |
12:59 ET | 200 | 31.36 |
01:01 ET | 400 | 31.44 |
01:03 ET | 624 | 31.43 |
01:06 ET | 335 | 31.43 |
01:08 ET | 779 | 31.47 |
01:10 ET | 400 | 31.4575 |
01:12 ET | 1000 | 31.53 |
01:14 ET | 1285 | 31.38 |
01:15 ET | 100 | 31.43 |
01:17 ET | 906 | 31.495 |
01:19 ET | 223 | 31.505 |
01:21 ET | 4473 | 31.57 |
01:24 ET | 2430 | 31.575 |
01:26 ET | 700 | 31.48 |
01:28 ET | 603 | 31.485 |
01:30 ET | 841 | 31.485 |
01:32 ET | 927 | 31.51 |
01:33 ET | 1190 | 31.53 |
01:35 ET | 2817 | 31.47 |
01:37 ET | 2333 | 31.5 |
01:39 ET | 656 | 31.55 |
01:42 ET | 1000 | 31.53 |
01:44 ET | 1876 | 31.595 |
01:48 ET | 623 | 31.62 |
01:50 ET | 345 | 31.56 |
01:51 ET | 2881 | 31.715 |
01:53 ET | 1067 | 31.715 |
01:55 ET | 5597 | 31.685 |
01:57 ET | 3444 | 31.8 |
02:00 ET | 2767 | 31.905 |
02:02 ET | 536 | 31.875 |
02:04 ET | 2775 | 31.73 |
02:06 ET | 567 | 31.73 |
02:08 ET | 508 | 31.81 |
02:09 ET | 3742 | 31.68 |
02:11 ET | 100 | 31.68 |
02:13 ET | 240 | 31.72 |
02:15 ET | 3131 | 31.755 |
02:18 ET | 800 | 31.76 |
02:20 ET | 1712 | 31.815 |
02:22 ET | 737 | 31.88 |
02:24 ET | 1600 | 31.79 |
02:26 ET | 337 | 31.815 |
02:27 ET | 1210 | 31.79 |
02:29 ET | 300 | 31.805 |
02:31 ET | 667 | 31.74 |
02:33 ET | 414 | 31.815 |
02:36 ET | 5934 | 31.55 |
02:38 ET | 2694 | 31.63 |
02:40 ET | 334 | 31.675 |
02:42 ET | 306 | 31.65 |
02:44 ET | 1252 | 31.715 |
02:45 ET | 1000 | 31.675 |
02:47 ET | 515 | 31.665 |
02:49 ET | 2158 | 31.67 |
02:51 ET | 1600 | 31.62 |
02:54 ET | 769 | 31.62 |
02:56 ET | 3461 | 31.655 |
02:58 ET | 6164 | 31.675 |
03:00 ET | 1001 | 31.68 |
03:02 ET | 3937 | 31.785 |
03:03 ET | 1453 | 31.82 |
03:05 ET | 6648 | 31.63 |
03:07 ET | 1990 | 31.7 |
03:09 ET | 636 | 31.7 |
03:12 ET | 3312 | 31.71 |
03:14 ET | 1244 | 31.74 |
03:16 ET | 2358 | 31.65 |
03:18 ET | 5034 | 31.82 |
03:20 ET | 3369 | 31.75 |
03:21 ET | 2878 | 31.67 |
03:23 ET | 3799 | 31.705 |
03:25 ET | 591 | 31.72 |
03:27 ET | 3468 | 31.74 |
03:30 ET | 2154 | 31.7 |
03:32 ET | 4100 | 31.57 |
03:34 ET | 3307 | 31.43 |
03:36 ET | 8967 | 31.3 |
03:38 ET | 8832 | 31.42 |
03:39 ET | 2095 | 31.53 |
03:41 ET | 6316 | 31.55 |
03:43 ET | 2353 | 31.63 |
03:45 ET | 8755 | 31.46 |
03:48 ET | 2888 | 31.41 |
03:50 ET | 1599 | 31.49 |
03:52 ET | 3548 | 31.62 |
03:54 ET | 10460 | 31.555 |
03:56 ET | 8644 | 31.61 |
03:57 ET | 23087 | 31.6075 |
03:59 ET | 11126 | 31.57 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
CG Oncology Inc | 2.0B | -28.0x | --- |
Janux Therapeutics Inc | 2.1B | -34.2x | --- |
Rocket Pharmaceuticals Inc | 1.9B | -7.5x | --- |
Structure Therapeutics Inc | 2.2B | -16.9x | --- |
Vera Therapeutics Inc | 1.8B | -17.7x | --- |
Apogee Therapeutics Inc | 2.2B | -19.3x | --- |
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.0B |
---|---|
Revenue (TTM) | $539.0K |
Shares Outstanding | 66.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.13 |
Book Value | $2.91 |
P/E Ratio | -28.0x |
Price/Sales (TTM) | 3,773.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -12,652.50% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.